1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAdara Development USA is sponsored by Adara Development USA. Delivers quality health and education services to impoverished communities, emphasizing maternal, newborn, and child health programs.
Get alerted about grants like this
Save a search for “Adara Development USA” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Supporting Communities In Poverty | The Adara Group We believe in using the power of business and partnership to change the lives of people in poverty. International Development We envision a world where every person has access to quality health and education services, no matter where they live. We bring this to life by delivering leading programmes across Maternal, Newborn and Child Health, and Remote Community Development.
Since 1998, we have touched the lives of more than 700,000 people living in poverty as well as countless others through our influence, networks and knowledge sharing. For more than 25 years, we’ve been forging partnerships across sectors and countries. Thanks to our business-for-purpose model, 100% of every donation supports our work with people in some of the world’s remotest places.
We’re a corporate advisory firm with a difference, providing strategic advice to leading Australian companies. The fees we generate support our work with people living in poverty. Adara Partners provides independent advice, second opinions, complex commercial problem solving and capital raising advice.
Learn about Adara Partners Our advisory services are provided by our Panel of 15 of the best-known advisors in Australia. They lead engagements on behalf of Adara without recompense. Direct, undiluted access to these individuals working collaboratively is not available elsewhere.
We’ve built an impressive track record advising some of Australia’s largest companies on critical transactions including equity capital markets, mergers and acquisitions, and complex commercial problem solving. Our clients have included Atlas Arteria, Commonwealth Bank, Sydney Airport, the Paul Ramsay Foundation and Wesfarmers. Our mission is to bridge the world of business and the world of people in extreme poverty.
The Adara Group consists of an international development organisation, Adara Development, and two corporate advisory businesses, Adara Partners and Adara Advisors. We have two very different parts but one shared purpose: to bring quality health and education services to communities in need.
Meet Hope and Baby Eva: quality newborn care in Uganda Safely delivering twins in remote Humla Nepal: Anita’s story How Baby Ubuntu is supporting children with disabilities in Uganda Sharing Knowledge & Forging Friendships Across the world A Stone of Hope – By Audette Exel Daniel Kabugo’s Journey to Adara’s Uganda Country Director From a child living on the streets to transforming mental health care in Uganda: Enoch’s story Gita’s journey to safe motherhood in remote Nepal Supporting children with neurodisabilities: Vivian and James’ story Accessing quality education in remote Nepal: Lhamu’s story Supporting young mothers in Uganda through the Adara Youth Community Centre: Edith’s story The AdaraNewborn Training Programme: Equipping health workers to save newborn lives Learn about how we’re halving maternal and newborn deaths across 10 health facilities in Uganda in this 30-minute film.
It chronicles the development of the Kiwoko Hospital neonatal intensive care unit (NICU) in rural Uganda and our plans for the future. 100% of donations directly fund our projects. The Adara businesses fund all our core support, administration and emergency project costs.
Based on current listing details, eligibility includes: Nonprofits and NGOs in developing countries. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
-Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop, standardize, and validate new and innovative assays, integrated strategies, or batteries of assays that determine or predict specific organ toxicities (e.g., ocular, dermal, hematotoxicity, cardiotoxicity, gastrointestinal toxicity, hepatotoxicity, nephrotoxicity, ototoxicity, olfactory loss, bladder toxicity, neurotoxicity, pulmonary toxicity, endocrine toxicity, and pancreatic beta cell toxicity), resulting from both acute and chronic exposures to various chemicals, environmental pollutants, biologics and therapeutic molecules or drugs. In addition, this FOA encourages the development, standardization, and validation of new models of arthritis, convulsion, infection and shock. New approaches for high throughput toxicity screening that involves the use of molecular endpoints, computer modeling, proteomics, genomics and epigenomics and the development of virtual tissues are also encouraged as are development of 3-dimensional organ models for toxicity evaluation. -Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-09-007, which encourages applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. Funding Opportunity Number: PA-09-006. Assistance Listing: 93.113,93.173,93.361,93.389,93.837,93.846,93.847,93.848,93.849,93.859,93.867. Funding Instrument: G. Category: ED,ENV,FN,HL.
Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. Funding Opportunity Number: PAR-10-286. Assistance Listing: 93.393,93.394,93.395,93.396. Funding Instrument: CA. Category: ED,HL. Award Amount: Up to $150K per award.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.